Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883127 | 1.00 | MMP7 (0.42) | MMP7TSHRLMNAMEN1KMT2A | |
| SCHEMBL6645607 | 0.86 | MMP7 (0.57) | MMP7LMNAMEN1KMT2AMAPT | |
| SCHEMBL6806731 | 0.86 | MMP7 (0.57) | MMP7LMNAMEN1KMT2AMAPT | |
| SCHEMBL6650377 | 0.86 | MMP7 (0.57) | MMP7LMNAMEN1KMT2AMAPT | |
| SCHEMBL6643214 | 0.84 | MMP7 (0.42) | MMP7LMNAMEN1KMT2AGAA | |
| SCHEMBL6807235 | 0.84 | MMP7 (0.42) | MMP7LMNAMEN1KMT2AGAA | |
| SCHEMBL6807231 | 0.84 | MMP7 (0.42) | MMP7LMNAMEN1KMT2AGAA | |
| SCHEMBL6811849 | 0.83 | DRD3 (0.36) | TSHRLMNAMEN1KMT2AGAA | |
| SCHEMBL6646411 | 0.83 | DRD3 (0.36) | TSHRLMNAMEN1KMT2AGAA | |
| SCHEMBL3934582 | 0.81 | MAPT (0.39) | MMP7TSHRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| EP-1417181-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| WO-2003014092-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | MMP7 16/4885TSHR 4597/4885LMNA 1148/4885 |
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | MMP7 18/4885TSHR 2000/4885LMNA 3353/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | MMP7 18/4885TSHR 4551/4885LMNA 1250/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | MMP7 16/4885TSHR 4597/4885LMNA 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.